• If you are wondering whether GE HealthCare Technologies is attractively priced or starting to look stretched, the current setup offers plenty for valuation focused investors to unpack.
• The stock last closed at US$74.66, with returns of 2.0% over 7 days, 7.2% over 30 days, a 9.9% decline year to date, and a 20.0% gain over 1 year, which gives a mixed picture of recent performance.
• Recent coverage has centered on GE HealthCare Technologies as a standalone medical technology player following its separation from General Electric. This has kept attention on its individual capital allocation and balance sheet decisions. There has also been ongoing interest in how the company positions itself against peers in medical equipment and healthcare technology, which can influence how the stock is priced.
• Right now the company has a value score of 6/6, suggesting that all six of Simply Wall St's valuation checks see the stock as undervalued. The sections that follow will walk through these methods before finishing with a broader way to think about what that valuation really means for you.

Approach 1: GE HealthCare Technologies Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s dollars, giving an estimate of what the entire business might be worth right now.

For GE HealthCare Technologies, the model used is a 2 Stage Free Cash Flow to Equity approach built on cash flow projections. The company’s latest twelve month free cash flow is about US$1.55b. Analyst inputs and Simply Wall St extrapolations indicate free cash flow of US$2.42b in 2028, with interim estimates such as around US$1.66b in 2026 and US$2.12b in 2027, all in US$ terms.

When these projected cash flows over the next decade are discounted back, the model arrives at an estimated intrinsic value of US$110.82 per share. Compared with the recent share price of US$74.66, this indicates a 32.6% discount, meaning the shares are currently priced below this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests GE HealthCare Technologies is undervalued by 32.6%. Track this in your watchlist or portfolio, or discover 60 more high quality undervalued stocks.

Approach 2: GE HealthCare Technologies Price vs Earnings

For a profitable company, the P/E ratio is a useful way to see how much you are paying for each dollar of earnings. This makes it a common starting point when you are comparing established businesses.

What counts as a “normal” P/E really depends on how the market views a company’s growth potential and risk profile. Higher growth and lower perceived risk can support a higher multiple, while slower growth or higher uncertainty often come with a lower one.

GE HealthCare Technologies currently trades on a P/E of 16.35x, compared with about 26.02x for the Medical Equipment industry and a peer average of 34.05x. Simply Wall St’s Fair Ratio for the stock is 27.80x, which reflects what its P/E might be given factors such as earnings growth, industry, profit margin, market cap and risk characteristics.

This Fair Ratio goes further than a simple industry or peer comparison because it adjusts for company specific traits, rather than assuming all businesses in the same sector deserve the same multiple.

Comparing the Fair Ratio of 27.80x with the current P/E of 16.35x suggests the shares are trading below this proprietary estimate.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your GE HealthCare Technologies Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach your own story about GE HealthCare Technologies to the numbers by linking a view on its products, tariffs, partnerships and AI imaging pipeline to clear forecasts for revenue, earnings and margins. These then flow through to a fair value you can compare with the current price to help decide if the stock looks attractive or expensive for you at any point in time.

On the Community page, millions of investors can use Narratives as an accessible tool that stays up to date as new earnings, news and product clearances are reflected in forecasts. Your fair value view adjusts automatically instead of staying frozen.

For example, one investor might focus on the analyst consensus fair value of about US$91.74 and see it as reasonable. A more optimistic investor might align with the US$110 high target that leans heavily on AI imaging advances and product growth. A more cautious investor may be closer to the US$75 low target that gives more weight to tariff and regulatory risks. Each creates a different but transparent Narrative that you can compare with your own expectations.

Do you think there's more to the story for GE HealthCare Technologies? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.